129488-09-1

Basic information

• Product Name: N-(1)-BOC-5-NITRO-INDAZOLE
• Synonyms: N-(1)-BOC-5-NITRO-INDAZOLE;tert-butyl 5-nitro-1H-indazole-1-carboxylate;tert-butyl 5-nitro-1H-indazol-1-carboxylate;1H-Indazole-1-carboxylic acid, 5-nitro-, 1,1-diMethylethyl ester;5-Nitroindazole-1-carboxylic acid tert-butyl ester
• CAS NO: 129488-09-1
• Molecular Formula: C₁₂H₁₃N₃O₄
• Molecular Weight: 263.25
• Mol File: 129488-09-1.mol

Chemical Properties

• Boiling Point: 406.1°Cat760mmHg
• Flash Point: 199.4°C
• Appearance: /
• Density: 1.34g/cm³
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.606
• CAS DataBase Reference: N-(1)-BOC-5-NITRO-INDAZOLE(CAS DataBase Reference)
• NIST Chemistry Reference: N-(1)-BOC-5-NITRO-INDAZOLE(129488-09-1)
• EPA Substance Registry System: N-(1)-BOC-5-NITRO-INDAZOLE(129488-09-1)

Safety Data

• Hazardous Substances Data: 129488-09-1(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Chemistry:
N-(1)-BOC-5-NITRO-INDAZOLE is used as a key intermediate in the synthesis of pharmaceutical compounds for its ability to be further modified and functionalized to create new drug candidates. Its presence in the molecule allows for the development of potential therapeutic agents that can be tailored to target specific biological pathways or receptors.
Used in Agrochemical Development:
In the agrochemical industry, N-(1)-BOC-5-NITRO-INDAZOLE is used as a precursor in the creation of new pesticides or herbicides. N-(1)-BOC-5-NITRO-INDAZOLE's reactivity and structural features enable the design of molecules that can effectively control or eliminate unwanted plant species or pests, thereby enhancing crop yields and quality.
Used in Organic Synthesis:
N-(1)-BOC-5-NITRO-INDAZOLE is utilized as a versatile building block in organic synthesis for its potential to be transformed into a range of different chemical entities. The BOC protecting group can be selectively removed under mild conditions, unveiling the amine functionality for further reactions, while the nitro group can be reduced or otherwise modified to introduce various functional groups.
Used in Research and Development:
In academic and industrial research settings, N-(1)-BOC-5-NITRO-INDAZOLE serves as a valuable tool for exploring new chemical reactions and mechanisms. Its unique properties can provide insights into the reactivity of related compounds and contribute to the advancement of synthetic methodologies.

InChI:InChI=1/C12H13N3O4/c1-12(2,3)19-11(16)14-10-5-4-9(15(17)18)6-8(10)7-13-14/h4-7H,1-3H3

Upstream product

• 24424-99-5 di-tert-butyl dicarbonate 
• 5401-94-5 5-nitroindazole 

Downstream Products

• 129488-10-4 5-Amino-indazole-1-carboxylic acid tert-butyl ester 
• 916991-31-6 5-(1-benzyl-piperidin-3-ylamino)-indazole-1-carboxylic acid tert-butyl ester 
• 1404375-45-6 C₂₆H₃₁N₅O₃S 
• 1404375-54-7 C₂₈H₂₉N₅O₃ 
• 1404375-56-9 C₂₈H₂₉N₅O₃ 
• 1404375-74-1 3-({3-[(1H-indazol-5-yl)amino]piperidin-1-yl}methyl)benzoic acid 
• 1404375-73-0 5-[1-(3-carboxy-benzyl)-piperidin-3-ylamino]-indazole-1-carboxylic acid tert-butyl ester 
• 1404375-76-3 5-[1-(3-carboxymethylbenzyl)-piperidin-3-ylamino]-indazole 
• 1404375-75-2 5-[1-(3-carboxymethyl-benzyl)-piperidin-3-ylamino]-indazole-1-carboxylic acid tert-butyl ester 
• 1404375-21-8 C₂₄H₃₀N₄O₂ 

Relevant articles and documents

Synthesis of novel N-Aryl-1H-indazolamines from amino-1H-indazoles and arylboronic acids

An efficient and high-yielding synthesis of N-aryl-1H-indazolamines from amino-1H-indazole and arylboronic acids are described. In this study a series of novel N-aryl-1H-indazolamines (1a-i) were synthesized using arylboronic acids and amino-1 H-indazoles

EP300/CREBBP INHIBITOR

The present invention provides a compound having excellent histone acetyltransferase inhibitory activity against EP300 and/or CREBBP, or a pharmacologically acceptable salt thereof. The compound is represented by the following formula (1) or a pharmacologically acceptable salt thereof: wherein ring Q1, ring Q2, R1, R2, R3 and R4 respectively have the same meanings as defined in the specification.

RHO-ASSOCIATED PROTEIN KINASE INHIBITOR, PHARMACEUTICAL COMPOSITION COMPRISING THE SAME, AS WELL AS PREPARATION METHOD AND USE THEREOF

The present invention relates to a Rho-associated protein kinase inhibitor of Formula (I), a pharmaceutical composition comprising the same, a preparation method thereof, and use thereof for the prevention or treatment of a disease mediated by the Rho-associated protein kinase (ROCK).

RHO-ASSOCIATED PROTEIN KINASE INHIBITOR, PHARMACEUTICAL COMPOSITION COMPRISING THE SAME, AS WELL AS PREPARATION METHOD AND USE THEREOF

The present invention relates to a Rho-associated protein kinase inhibitor of Formula (I), a pharmaceutical composition comprising the same, a preparation method thereof, and use thereof for the prevention or treatment of a disease mediated by the Rho-associated protein kinase (ROCK).

HEPARAN SULFATE BIOSYNTHESIS INHIBITORS FOR THE TREATMENT OF DISEASES

Described herein are compounds of Formula I, methods of making such compounds, pharmaceutical compositions and medicaments containing such compounds, and methods of using such compounds to treat or prevent diseases or conditions in need of inhibition of heparan sulfate biosynthesis.

NOVEL ROCK INHIBITORS

The present invention relates to new kinase inhibitors of Formula (I), wherein X is oxygen, —NH—, or a direct bond; Y is —NH— or a direct bond; n is an integer from 0 to 4; m is an integer from 0 to 4; Cy represents a bivalent radical consisting of a satured (poly)cycle, including fused, bi-, spiro or bridged carbocycles and heterocycles; in particular selected from the group consisting of: Formula (II), Ar is selected from the group comprising: Formula (III), R2 is hydrogen or methyl; R8 is hydrogen, methyl, halogen, or alkynyl; R1 is an aryl or heteroaryl more specifically ROCK inhibitors, compositions, in particular pharmaceuticals, comprising such inhibitors, and to uses of such inhibitors in the treatment and prophylaxis of disease. In particular, the present invention relates to new ROCK inhibitors, compositions, in particular pharmaceuticals, comprising such inhibitors, and to uses of such inhibitors in the treatment and prophylaxis of disease. In addition, the invention relates to methods of treatment and use of said compounds in the manufacture of a medicament for the application to a number of therapeutic indications including sexual dysfunction, inflammatory diseases, ophthalmic diseases and Respiratory diseases.

NOVEL ROCK INHIBITORS

The present invention relates to new kinase inhibitors, more specifically ROCK inhibitors, compositions, in particular pharmaceuticals, comprising such inhibitors, and to uses of such inhibitors in the treatment and prophylaxis of disease. In particular, the present invention relates to new ROCK inhibitors, compositions, in particular pharmaceutic-als, comprising such inhibitors, and to uses of such inhibitors in the treatment and prophylaxis of disease. In addition, the invention relates to methods of treatment and use of said compounds in the manufacture of a medicament for the ap-plication to a number of therapeutic indications including sexual dysfunction, inflammatory diseases, ophthalmic dis-eases and Respiratory diseases. Compounds of the invention display soft drug characteristics, i.e. they are rapidly inactivated upon entry in the systemic circulation. Therefore, they allow for reduced systemic exposure to functionally active ROCK inhibitors

NOVEL ROCK INHIBITORS

The present invention relates to new kinase inhibitors, more specifically ROCK inhibitors, compositions, in particular pharmaceuticals, comprising such inhibitors, and to uses of such inhibitors in the treatment and prophylaxis of disease. In particular, the present invention relates to new ROCK inhibitors, compositions, in particular pharmaceuticals, comprising such inhibitors, and to uses of such inhibitors in the treatment and prophylaxis of disease. In addition, the invention relates to methods of treatment and use of said compounds in the manufacture of a medicament for the application to a number of therapeutic indications including sexual dysfunction, inflammatory diseases, ophthalmic diseases and Respiratory diseases.

QUINAZOLINONE AND FUSED PYRIMIDINONE COMPOUNDS AND THEIR USE IN TREATING SODIUM CHANNEL-MEDIATED DISEASES OR CONDITIONS

This invention is directed to compounds of formula (I): wherein (A), n, R1, R2 and R3 are as defined herein, as a stereoisomer, enantiomer, tautomer thereof or mixtures thereof; or a pharmaceutically acceptable salt, solvate or prodrug thereof, for the treatment and/or prevention of sodium channel-mediated diseases or conditions, such as pain.

N-ureidoheterocycloalkyl-piperidines as modulators of chemokine receptor activity

The present application describes modulators of CCR3 of formula (I): or pharmaceutically acceptable salt forms thereof, useful for the prevention of asthma and other allergic diseases.